Section Arrow
Quote
RIGL.NASDAQ
- Rigel Pharmaceuticals Inc
Quotes are at least 15-min delayed:2026/03/06 20:54 EST
Regular Hours
Last
 28.84
-0.66 (-2.24%)
Day High 
29.2 
Prev. Close
29.5 
1-M High
36.95 
Volume 
18.74K 
Bid
28.68
Ask
29
Day Low
28.24 
Open
28.81 
1-M Low
28.01 
Market Cap 
535.79M 
Currency 美元 
P/E 4.77 
%Yield -- 
10-SMA 33.61 
20-SMA 34.19 
50-SMA 37.52 
52-W High 52.24 
52-W Low 15.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
6.19/3.92
Enterprise Value
588.20M
Balance Sheet
Book Value Per Share
6.48
Cash Flow
Cash Flow Yield
0.13
Income Statement
Total Revenue
179.28M
Operating Revenue Per Share
7.29
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
DAWNDay One Biopharmaceuticals21.21+8.44+66.09%-- 
IOVAIovance Biotherapeutics5.135+0.54+11.75%-- 
QNCXQuince Therapeutics0.1023-0.0025-2.39%-- 
EDSAEdesa Biotech6.53+2.92+80.89%-- 
IBRXImmunityBio8.65-0.3001-3.35%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.